285 related articles for article (PubMed ID: 19880176)
1. The effect of PEGylation of mesoporous silica nanoparticles on nonspecific binding of serum proteins and cellular responses.
He Q; Zhang J; Shi J; Zhu Z; Zhang L; Bu W; Guo L; Chen Y
Biomaterials; 2010 Feb; 31(6):1085-92. PubMed ID: 19880176
[TBL] [Abstract][Full Text] [Related]
2. In vivo biodistribution and urinary excretion of mesoporous silica nanoparticles: effects of particle size and PEGylation.
He Q; Zhang Z; Gao F; Li Y; Shi J
Small; 2011 Jan; 7(2):271-80. PubMed ID: 21213393
[TBL] [Abstract][Full Text] [Related]
3. Interaction of mesoporous silica nanoparticles with human red blood cell membranes: size and surface effects.
Zhao Y; Sun X; Zhang G; Trewyn BG; Slowing II; Lin VS
ACS Nano; 2011 Feb; 5(2):1366-75. PubMed ID: 21294526
[TBL] [Abstract][Full Text] [Related]
4. Biofunctionalized phospholipid-capped mesoporous silica nanoshuttles for targeted drug delivery: improved water suspensibility and decreased nonspecific protein binding.
Wang LS; Wu LC; Lu SY; Chang LL; Teng IT; Yang CM; Ho JA
ACS Nano; 2010 Aug; 4(8):4371-9. PubMed ID: 20731423
[TBL] [Abstract][Full Text] [Related]
5. The shape effect of mesoporous silica nanoparticles on biodistribution, clearance, and biocompatibility in vivo.
Huang X; Li L; Liu T; Hao N; Liu H; Chen D; Tang F
ACS Nano; 2011 Jul; 5(7):5390-9. PubMed ID: 21634407
[TBL] [Abstract][Full Text] [Related]
6. The effect of the shape of mesoporous silica nanoparticles on cellular uptake and cell function.
Huang X; Teng X; Chen D; Tang F; He J
Biomaterials; 2010 Jan; 31(3):438-48. PubMed ID: 19800115
[TBL] [Abstract][Full Text] [Related]
7. Mesoporous silica nanoparticles improve magnetic labeling efficiency in human stem cells.
Liu HM; Wu SH; Lu CW; Yao M; Hsiao JK; Hung Y; Lin YS; Mou CY; Yang CS; Huang DM; Chen YC
Small; 2008 May; 4(5):619-26. PubMed ID: 18491363
[TBL] [Abstract][Full Text] [Related]
8. Internalization of mesoporous silica nanoparticles induces transient but not sufficient osteogenic signals in human mesenchymal stem cells.
Huang DM; Chung TH; Hung Y; Lu F; Wu SH; Mou CY; Yao M; Chen YC
Toxicol Appl Pharmacol; 2008 Sep; 231(2):208-15. PubMed ID: 18519141
[TBL] [Abstract][Full Text] [Related]
9. Effect of size on the cellular endocytosis and controlled release of mesoporous silica nanoparticles for intracellular delivery.
Gan Q; Dai D; Yuan Y; Qian J; Sha S; Shi J; Liu C
Biomed Microdevices; 2012 Apr; 14(2):259-70. PubMed ID: 22124885
[TBL] [Abstract][Full Text] [Related]
10. Impacts of mesoporous silica nanoparticle size, pore ordering, and pore integrity on hemolytic activity.
Lin YS; Haynes CL
J Am Chem Soc; 2010 Apr; 132(13):4834-42. PubMed ID: 20230032
[TBL] [Abstract][Full Text] [Related]
11. Critical Features for Mesoporous Silica Nanoparticles Encapsulated into Erythrocytes.
Chen ZA; Wu SH; Chen P; Chen YP; Mou CY
ACS Appl Mater Interfaces; 2019 Feb; 11(5):4790-4798. PubMed ID: 30624037
[TBL] [Abstract][Full Text] [Related]
12. Mesoporosity and functional group dependent endocytosis and cytotoxicity of silica nanomaterials.
Tao Z; Toms BB; Goodisman J; Asefa T
Chem Res Toxicol; 2009 Nov; 22(11):1869-80. PubMed ID: 19817448
[TBL] [Abstract][Full Text] [Related]
13. Effect of surface functionalization of MCM-41-type mesoporous silica nanoparticles on the endocytosis by human cancer cells.
Slowing I; Trewyn BG; Lin VS
J Am Chem Soc; 2006 Nov; 128(46):14792-3. PubMed ID: 17105274
[TBL] [Abstract][Full Text] [Related]
14. Effect of polymer architecture on surface properties, plasma protein adsorption, and cellular interactions of pegylated nanoparticles.
Sant S; Poulin S; Hildgen P
J Biomed Mater Res A; 2008 Dec; 87(4):885-95. PubMed ID: 18228249
[TBL] [Abstract][Full Text] [Related]
15. Poly-L-lysine functionalized large pore cubic mesostructured silica nanoparticles as biocompatible carriers for gene delivery.
Hartono SB; Gu W; Kleitz F; Liu J; He L; Middelberg AP; Yu C; Lu GQ; Qiao SZ
ACS Nano; 2012 Mar; 6(3):2104-17. PubMed ID: 22385282
[TBL] [Abstract][Full Text] [Related]
16. Biocompatibility of mesoporous silica nanoparticles.
Asefa T; Tao Z
Chem Res Toxicol; 2012 Nov; 25(11):2265-84. PubMed ID: 22823891
[TBL] [Abstract][Full Text] [Related]
17. Inclusion of poorly soluble drugs in highly ordered mesoporous silica nanoparticles.
Thomas MJ; Slipper I; Walunj A; Jain A; Favretto ME; Kallinteri P; Douroumis D
Int J Pharm; 2010 Mar; 387(1-2):272-7. PubMed ID: 20025947
[TBL] [Abstract][Full Text] [Related]
18. Mesoporous silica nanoparticles for intracellular controlled drug delivery.
Vivero-Escoto JL; Slowing II; Trewyn BG; Lin VS
Small; 2010 Sep; 6(18):1952-67. PubMed ID: 20690133
[TBL] [Abstract][Full Text] [Related]
19. Mesoporous silica nanoparticles for intracellular delivery of membrane-impermeable proteins.
Slowing II; Trewyn BG; Lin VS
J Am Chem Soc; 2007 Jul; 129(28):8845-9. PubMed ID: 17589996
[TBL] [Abstract][Full Text] [Related]
20. A robust graft-to strategy to form multifunctional and stealth zwitterionic polymer-coated mesoporous silica nanoparticles.
Zhu Y; Sundaram HS; Liu S; Zhang L; Xu X; Yu Q; Xu J; Jiang S
Biomacromolecules; 2014 May; 15(5):1845-51. PubMed ID: 24670217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
